Test Background Most patients can safely take abacavir; however, a small number of patients experience a severe side effect known as abacavir hypersensitivity. The most common symptoms are skin rash, fever, nausea, vomiting and diarrhea. About 5% of patients who take abacavir experience abacavir hypersensitivity. This reaction can sometimes be very serious and in some cases can cause death. Patients who are HLA-B*57:01 are much more likely to have this reaction than patients who do not. Therefore, patients with the HLA-B*57:01 gene should not take abacavir. Approximately 5-8% of Europeans, 1-2% of Asians, and 2% of Africans have this gene.
Screening for Abacavir Hypersensitivity
Reference Range Negative
Sample Required 5-10 mL Whole Blood
Sample Container EDTA ( 6 ml pink top)
Sample Volume 5 mls
Transport/Storage Samples must be sent via first class post or courier
Turnaround Time 14 days
Samples must be sent via first class post or courier
The laboratory is accredited for this test by the European Federation of Immunogenetics (EFI) however due to a change in platform it is currently awaiting UKAS accreditation under extension to scope.